Development and Pilot Application of a Solution-Focused Intervention for Social Isolation in Elderly Diabetic Foot Patients
Construction and Preliminary Application of a Solution-Focused Model-Based Intervention Program for Social Isolation in Elderly Patients With Diabetic Foot Ulcers
The goal of this interventional study is to develop and preliminarily evaluate a solution-focused model-based intervention program for reducing social isolation in elderly patients with diabetic foot ulcers. It will also learn about the feasibility and safety of the intervention program. The main questions it aims to answer are:
Does the solution-focused intervention program effectively reduce social isolation levels in elderly patients with diabetic foot ulcers?
What effects does the intervention have on patients' foot self-care behaviors, social participation, social support, depressive symptoms, and glycemic control?
Researchers will compare an intervention group (receiving the solution-focused intervention combined with routine nursing care) to a control group (receiving routine nursing care only) to see if the intervention program works to alleviate social isolation in this population.
Participants will:
Complete a set of validated questionnaires (including assessments of social isolation, foot self-care behaviors, social support, social participation, and depressive symptoms) and undergo fasting blood glucose measurement at four time points: baseline, after 3 intervention sessions, at intervention completion, and 1-month post-intervention
Attend 5 weekly sessions (0.5 -1 hours each) of the solution-focused intervention program, which follows five core steps: problem description, goal setting, exception exploration, feedback, and progress evaluation (intervention group only)
Receive routine nursing care including blood glucose monitoring, dietary management, medication guidance, psychological support, and activity instructions (both groups)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Junnan Song
- Número de teléfono: +86 18712096043
- Correo electrónico: junnansong00@163.com
Ubicaciones de estudio
-
-
Anhui
-
Hefei, Anhui, Porcelana, 230031
- The First Affiliated Hospital of Anhui Medical University
-
Contacto:
- Junnan Song
- Número de teléfono: +86 18712096043
- Correo electrónico: junnansong00@163.com
-
Contacto:
- Correo electrónico: junnansong00@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
(1) Meet the current Chinese criteria for older adults, aged ≥60 years;
(2) Clinically diagnosed with diabetic foot (DF);
(3) Voluntarily agree to participate in this study after being informed of the study purpose by the researcher.
Exclusion Criteria:
(1) Severe cognitive impairment or mental disorders: patients definitively diagnosed with Parkinson's disease, senile dementia, or severe depression by a Class II-A or higher hospital; or those with a score below 9 on the Mini-Mental State Examination (MMSE) indicating severe cognitive impairment;
(2) Severe communication impairment: patients unable to communicate normally with others due to hearing impairment, speech impairment, or other related conditions;
(3) Patients unable to complete the questionnaire survey for any reason;
(4) Patients currently participating in other trials that may affect the results of this study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Grupo de control
|
|
|
Otro: Grupo de intervención
|
Researchers will compare an intervention group (receiving the solution-focused intervention plus routine care) to a control group (receiving routine care only). Participants will complete validated questionnaires (LSNS-6, NAFF, SSRS, IPA, CES-D-10) and undergo fasting blood glucose measurement at four time points: baseline, after 3 sessions, at intervention completion, and 1-month post-intervention. The intervention group will attend 5 weekly sessions (1-1.5 hours each) following five core steps: problem description, goal setting, exception exploration, feedback, and progress evaluation. Both groups receive routine care including blood glucose monitoring, dietary management, medication guidance, psychological support, and activity instructions. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Level of Social Isolation
Periodo de tiempo: From enrollment to the end of treatment at 5 weeks
|
Measured by the Lubben Social Network Scale-6 (LSNS-6) , an abbreviated version of the original Lubben Social Network Scale developed by Lubben et al.
The LSNS-6 assesses social network status from two dimensions: family network (3 items) and friend network (3 items), totaling 6 items.
Each item is rated on a 6-point Likert scale (0 = none, 1 = one, 2 = two, 3 = three to four, 4 = five to eight, 5 = nine or more).
Total scores range from 0 to 30.
A total score <12 indicates social isolation.
Family network score <6 indicates family network isolation, and friend network score <6 indicates friend network isolation.
The Chinese version has demonstrated adequate internal consistency with a Cronbach's α of 0.832.
|
From enrollment to the end of treatment at 5 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Social support level
Periodo de tiempo: From enrollment to the end of treatment at 5 weeks.
|
Social support level measured by the Medical Outcomes Study Social Support Survey (MOS-SSS).
The MOS-SSS contains 19 items across four dimensions: emotional/informational support (8 items), tangible support (4 items), affectionate support (3 items), and positive social interaction (4 items).
Each item is rated on a 5-point Likert scale (1=none of the time, 5=all of the time).
Total scores are transformed to a 0-100 scale, with higher scores indicating better social support.
The Chinese version has demonstrated good reliability and validity, with a Cronbach's α of 0.91.
|
From enrollment to the end of treatment at 5 weeks.
|
|
Social participation level
Periodo de tiempo: From enrollment to the end of treatment at 5 weeks.
|
Social participation level measured by the Social Participation Scale.
This scale assesses the frequency and diversity of social activities across multiple domains, including family interactions, community activities, and social gatherings.
Each item is rated on a 5-point Likert scale (1=never, 5=very often).
Higher total scores indicate a higher level of social participation.
The scale has been validated in older adult populations with chronic diseases, demonstrating satisfactory psychometric properties with a Cronbach's α of 0.85.
|
From enrollment to the end of treatment at 5 weeks.
|
|
Depressive symptoms
Periodo de tiempo: From enrollment to the end of treatment at 5 weeks.
|
Depressive symptoms measured by the Patient Health Questionnaire-9 (PHQ-9).
The PHQ-9 consists of 9 items corresponding to the DSM-IV diagnostic criteria for major depressive disorder.
Each item is rated on a 4-point Likert scale (0=not at all, 1=several days, 2=more than half the days, 3=nearly every day) based on symptom frequency over the past two weeks.
Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms (0-5 minimal, 6-10 mild, 11-15 moderate, 16-20 moderately severe, 21-27 severe).
Cronbach's α=0.89.
|
From enrollment to the end of treatment at 5 weeks.
|
|
Glycemic control (fasting blood glucose)
Periodo de tiempo: From enrollment to the end of treatment at 5 weeks.
|
Glycemic control measured by fasting blood glucose (FBG) in millimoles per liter (mmol/L).
Venous blood samples are collected after an 8-hour overnight fast and analyzed using the standardized glucose oxidase method.
Lower FBG values indicate better glycemic control.
According to the Chinese Diabetes Society guidelines, normal FBG is 3.9-6.1 mmol/L.
This objective biomarker provides a reliable assessment of short-term glycemic status.
|
From enrollment to the end of treatment at 5 weeks.
|
|
Diabetic foot self-care behaviors
Periodo de tiempo: From enrollment to the end of treatment at 5 weeks.
|
Diabetic foot self-care behaviors measured by the Diabetic Foot Self-Care Behavior Scale.
This scale evaluates patients' adherence to recommended foot care practices, including daily foot inspection, proper washing and drying, moisturizing, nail care, appropriate footwear selection, and avoiding barefoot walking.
Items are rated on a 5-point Likert scale (1=never, 5=always).
Higher total scores indicate better adherence to diabetic foot self-care behaviors.
The scale has shown good reliability with a Cronbach's α of 0.88.
|
From enrollment to the end of treatment at 5 weeks.
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 81250948
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .